# argenx: Phase 1 study completed, 32 enrolled (Healthy Volunteer, Healthy Adult Participants)

**Score:** 50/100

| Field | Value |
|---|---|
| Sponsor | argenx |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Study to Assess the Bioequivalence of Efgartigimod PH20 SC Between Autoinjector and Prefilled Syringe in Healthy Adult Participants |
| NCT ID | NCT07782775 |
| Phase | Phase 1 |
| Status | completed |
| Conditions | Healthy Volunteer; Healthy Adult Participants |
| Intervention types | biological |
| Target enrollment | 32 |
| Site countries | Canada |
| Posted | 2026-08-24 |
| Planned start | 2026-06-19 |
| Event | Completed |
| Event date | 2026-09-23 |
| Last update posted | 2026-10-14 |

## Why this score
- Industry sponsor (buys outsourced services).
- Completed: closeout, analysis and the next study ahead.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07782775). Last refreshed: 2026-11-05T08:46:16.625Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.